高免疫グロブリン市場の2030年までの予測：タイプ別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、高免疫グロブリンの世界市場は2023年に20億1,000万米ドルを占め、2030年には36億9,000万米ドルに達すると予測されています。

高免疫グロブリンは、特定の病原体や抗原に対して高濃度の抗体を持つ個人の血漿から得られる抗体の特殊な製剤です。これらの抗体は、特定の疾病に罹患したりワクチン接種を受けたりしたドナーから採取され、その結果、免疫系が強固な抗体反応を産生します。その後、高免疫グロブリンは、高レベルの特異的抗体を含むように処理、精製、濃縮されます。これらの製剤は受動免疫に使用され、特定の感染症に対して即座に標的免疫を提供します。

さまざまな感染症の流行

感染症は引き続き世界の健康上の大きな課題となっており、標的を絞った効果的な治療法に対する需要はますます高まっています。特定の病原体と闘う抗体を高濃度に含む高免疫グロブリンは、このような疾患の予防と治療に役立っています。肝炎から狂犬病に至るまで、感染症の罹患率が増加していることから、ヘルスケア・システムは高免疫グロブリン製品への投資を促しています。世界が既知の感染症と新興の感染症の両方の脅威に直面しているため、高免疫グロブリンの需要は引き続き堅調に推移し、市場での存在感とこれらの疾患と闘うための新しい治療法の開発がさらに強化されると予想されます。

入手可能なドナーが限られている

高免疫グロブリンは、特定の病原体に対する特異的抗体を持っている個人に由来します。必要な抗体を持つ十分な数のドナーを見つけることは、困難で資源集約的なプロセスです。この限界は、特に有病率の低い疾患や新興感染症の脅威に対して、高免疫グロブリンの需要を満たすために生産を拡大することを困難にします。さらに、製品の品質と有効性を維持するためには、適格なドナーの一貫した持続可能な供給を確保することが不可欠です。この制約のため、高免疫グロブリン市場では、人工抗体の開発や、より効率的なドナーの募集・収集戦略などの革新的なアプローチにより、ドナーの利用可能性の制限を克服する必要があります。

ヘルスケア専門家の意識の高まり

医療従事者は、特定の感染症や病態に対する高免疫グロブリンの治療効果について知識を深めるにつれ、これらの特殊な免疫グロブリン製剤を患者に推奨・投与する可能性が高まる。認知度の向上は、早期の診断と治療につながり、患者の転帰を改善します。さらに、情報に精通したヘルスケア専門家は、既存の感染症および新興感染症の両方に対する高免疫グロブリンの研究開発および臨床利用の拡大に貢献することができます。これにより、製薬会社と医療従事者の協力関係が促進され、最終的に高免疫グロブリン療法の成長と利用しやすさが促進されるとともに、患者ケアと公衆衛生の結果が改善されます。

限られた保存期間

高免疫グロブリン製剤は一般的に保存期間が比較的短いため、保管、輸送、流通の面で物流上の課題が生じる可能性があります。サプライ・チェーン全体を通して必要な温度と保管条件を維持することは、複雑でコストがかかる可能性があります。この制約は、特に指定された期間内に需要を満たせなかった場合、製品の浪費を招き、経済的損失につながる可能性があります。また、賞味期限切れや製品不足を防ぐためには、効率的な在庫管理が必要となります。この脅威を軽減するためには、高免疫グロブリンをタイムリーかつ効果的な方法で患者に確実に届けるために、保管・保存技術の革新、保存期間の延長された製品、流通システムの改善が必要です。

COVID-19の影響：

COVID-19パンデミックは遠隔地医療の導入を加速し、在宅高免疫グロブリンの需要を増加させました。ヘルスケア施設を敬遠する人が増える中、これらの機器を使えば、自宅で血圧をモニターし、慢性疾患の管理に役立てることができます。遠隔健康相談や遠隔モニタリングが不可欠となり、デジタルやスマートフォン一体型のモニターが普及しています。パンデミックは、セルフケアと早期発見の重要性を強調し、この期間の血圧モニタリング技術の革新と利便性を促進しています。

予測期間中、病院・診療所セグメントが最大となる見込み

高免疫グロブリン市場において、病院と診療所は、これらの特殊な免疫グロブリン療法を必要とする患者のケアと投与の主要な拠点として重要です。これらのヘルスケア施設は、高免疫グロブリン製品の流通と利用の中心的存在であり、特定の感染症に対する診断、治療、予防措置の拠点となっています。病院や診療所は、高免疫グロブリンを必要とする疾患の診断、治療の実施、患者のケア管理を担っています。これらの病院や診療所はまた、高免疫グロブリンの利点についての認識を高める上で重要な支持者としての役割を果たし、多くの場合、これらの製品の調達と在庫を担当しています。高免疫グロブリン市場の成功と成長は、患者ケアと公衆衛生における病院や診療所の関与と積極的な役割と密接に結びついています。

予測期間中、狂犬病免疫グロブリン分野のCAGRが最も高くなると予測される

狂犬病免疫グロブリン分野は、狂犬病予防に対する意識の高まり、特定地域での狂犬病発生率の上昇、生産技術の向上などを背景に、予測期間中に大きな成長が見込まれます。政府やヘルスケア機関は、この公衆衛生上の懸念に対処するために狂犬病対策プログラムを開始しています。さらに、現在進行中の研究開発は、狂犬病免疫グロブリンの効率と価格の向上を目指しています。狂犬病の予防と治療において狂犬病免疫グロブリンが果たす重要な役割により、高免疫グロブリン市場は今後も成長を続けることが確実視されています。

最もシェアの高い地域：

北米の高免疫グロブリン市場は、近年力強い成長が見込まれています。この急成長は、特にハイリスク集団における受動免疫に対する意識の高まりに起因しています。感染症の罹患率が増加し、即効性のある標的免疫の必要性が需要を牽引しています。さらに、ヘルスケア機関、研究機関、製薬企業間の戦略的提携により、研究開発が加速しています。医療インフラが整備され、規制の枠組みが厳しく、医療支出が増加している北米は、高免疫グロブリン市場の成長をリードし続けると思われます。

CAGRが最も高い地域：

予測期間中、北米は有利な成長が見込まれます。高免疫グロブリンは、アジア太平洋地域のヘルスケアにおいて重要な役割を果たしています。これらの特殊な抗体製剤は、この多様で人口の多い地域で流行している様々な感染症への対応と予防に不可欠です。B型肝炎、狂犬病、破傷風などの疾病は、公衆衛生上の重大な問題です。さらに、アジア太平洋の広大な地域情勢と人口動態の多様性は、公衆衛生を守り、感染症の影響を軽減する上でこれらの製剤が重要であることを強調しており、この地域のヘルスケアの状況において不可欠な要素となっています。

無料のカスタマイズサービス：

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の高度免疫グロブリン市場：種類別

• B型肝炎免疫グロブリン
• 狂犬病免疫グロブリン
• Rho（D）免疫グロブリン
• 破傷風免疫グロブリン
• その他のタイプ

第6章 世界の高度免疫グロブリン市場：エンドユーザー別

• 病院とクリニック
• 血液銀行と寄付センター
• 政府機関
• 在宅ヘルスケア
• 製薬会社
• その他のエンドユーザー

第7章 世界の高度免疫グロブリン市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第8章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第9章 企業プロファイル

• ADMA Biologics
• Biotest
• China National Biotec Group Company Limited（CNBG）
• CSL Behring
• Emergent（Cangene）
• Grifols
• Hualan Bio
• Kamada
• Kedrion
• Shanghai Raas Blood Products Co. Ltd
• Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.

List of Tables

• Table 1 Global Hyperimmune Globulins Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
• Table 4 Global Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
• Table 5 Global Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
• Table 6 Global Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
• Table 7 Global Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 8 Global Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
• Table 9 Global Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 10 Global Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
• Table 11 Global Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
• Table 12 Global Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
• Table 13 Global Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
• Table 14 Global Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 15 North America Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
• Table 16 North America Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
• Table 17 North America Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
• Table 18 North America Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
• Table 19 North America Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
• Table 20 North America Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
• Table 21 North America Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 22 North America Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
• Table 23 North America Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 24 North America Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
• Table 25 North America Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
• Table 26 North America Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
• Table 27 North America Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
• Table 28 North America Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 29 Europe Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
• Table 30 Europe Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
• Table 31 Europe Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
• Table 32 Europe Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
• Table 33 Europe Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
• Table 34 Europe Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
• Table 35 Europe Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 36 Europe Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
• Table 37 Europe Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 38 Europe Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
• Table 39 Europe Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
• Table 40 Europe Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
• Table 41 Europe Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
• Table 42 Europe Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 43 Asia Pacific Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
• Table 44 Asia Pacific Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
• Table 45 Asia Pacific Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
• Table 46 Asia Pacific Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
• Table 47 Asia Pacific Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
• Table 48 Asia Pacific Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
• Table 49 Asia Pacific Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 50 Asia Pacific Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
• Table 51 Asia Pacific Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 52 Asia Pacific Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
• Table 53 Asia Pacific Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
• Table 54 Asia Pacific Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
• Table 55 Asia Pacific Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
• Table 56 Asia Pacific Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 57 South America Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
• Table 58 South America Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
• Table 59 South America Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
• Table 60 South America Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
• Table 61 South America Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
• Table 62 South America Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
• Table 63 South America Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 64 South America Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
• Table 65 South America Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 66 South America Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
• Table 67 South America Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
• Table 68 South America Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
• Table 69 South America Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
• Table 70 South America Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 71 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
• Table 72 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
• Table 73 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
• Table 74 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
• Table 75 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
• Table 76 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
• Table 77 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
• Table 78 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
• Table 79 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
• Table 80 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
• Table 81 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
• Table 82 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
• Table 83 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
• Table 84 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Hyperimmune Globulins Market is accounted for $2.01 billion in 2023 and is expected to reach $3.69 billion by 2030 growing at a CAGR of 9% during the forecast period. Hyperimmune globulins are specialized preparations of antibodies that are derived from the blood plasma of individuals who have a high concentration of antibodies against a specific pathogen or antigen. These antibodies are collected from donors who have been exposed to or vaccinated against a particular disease, resulting in their immune system producing a robust antibody response. Hyperimmune globulins are then processed, purified, and concentrated to contain high levels of specific antibodies. These preparations are used for passive immunization, providing immediate and targeted immunity against particular infections.

Market Dynamics:

Driver:

The prevalence of various infectious diseases

The infectious diseases continuing to pose significant global health challenges, there is an ever-growing demand for targeted and effective therapies. Hyperimmune globulins, containing high concentrations of specific pathogen-fighting antibodies, are instrumental in preventing and treating such diseases. The increasing incidence of infectious diseases, ranging from hepatitis to rabies, prompts healthcare systems to invest in hyperimmune globulin products, as they offer critical support for patients, especially in cases where conventional treatments may be limited. As the world faces both known and emerging infectious threats, the demand for hyperimmune globulins is expected to remain robust, further bolstering their market presence and the development of new therapies to combat these diseases.

Restraint:

Limited availability of donors

Hyperimmune globulins are derived from individuals who possess specific antibodies against a particular pathogen. Finding an adequate number of donors with the necessary antibodies can be a challenging and resource-intensive process. This limitation can result in difficulties in scaling up production to meet the demand for hyperimmune globulins, particularly for diseases with a low prevalence or for emerging infectious threats. Moreover, ensuring a consistent and sustainable supply of qualified donors is essential for maintaining product quality and efficacy. This constraint necessitates innovative approaches, such as the development of artificial antibodies or more efficient donor recruitment and collection strategies, to overcome the limited availability of donors in the hyperimmune globulins market.

Opportunity:

Growing awareness among healthcare professionals

As healthcare providers become more informed about the therapeutic benefits of hyperimmune globulins in addressing specific infectious diseases and conditions, they are more likely to recommend and administer these specialized immunoglobulin products to their patients. Enhanced awareness can lead to earlier diagnosis and treatment, resulting in better patient outcomes. Additionally, informed healthcare professionals can contribute to increased research, development, and clinical utilization of hyperimmune globulins for both existing and emerging infectious diseases. This can foster collaboration between pharmaceutical companies and healthcare practitioners, ultimately driving the growth and accessibility of hyperimmune globulin therapies, while improving patient care and public health outcomes.

Threat:

Limited shelf life

Hyperimmune globulin products typically have a relatively short shelf life, which can lead to logistical challenges in terms of storage, transportation, and distribution. Maintaining the required temperature and storage conditions throughout the supply chain can be complex and costly. This constraint can result in product wastage, especially if the demand is not met within the specified timeframe, leading to financial losses. It also necessitates efficient inventory management to prevent expiration and product shortages. To mitigate this threat, there is a need for innovations in storage and preservation techniques, extended shelf life products, and improved distribution systems to ensure that hyperimmune globulins reach patients in a timely and effective manner.

COVID-19 Impact:

The COVID-19 pandemic has accelerated the adoption of remote healthcare, increasing the demand for home Hyperimmune Globulins. With more people avoiding healthcare facilities, these devices allow individuals to monitor their blood pressure from home, aiding in the management of chronic conditions. Telehealth consultations and remote monitoring have become essential, making digital and smartphone-integrated monitors more popular. The pandemic has underscored the importance of self-care and early detection, driving innovation and convenience in blood pressure monitoring technology during this period.

The hospitals & clinics segment is expected to be the largest during the forecast period

Hospitals and clinics are significant in the hyperimmune globulins market as primary points of care and administration for patients in need of these specialized immunoglobulin therapies. These healthcare facilities are central in the distribution and utilization of hyperimmune globulin products, serving as hubs for diagnosis, treatment, and preventive measures against specific infectious diseases. Hospitals and clinics are responsible for diagnosing conditions that require hyperimmune globulins, administering treatments, and managing patient care. They also serve as key advocates in raising awareness about the benefits of hyperimmune globulins and, in many cases, are responsible for procuring and stocking these products. The success and growth of the hyperimmune globulins market are closely tied to the engagement and proactive role of hospitals and clinics in patient care and public health.

The rabies immunoglobulins segment is expected to have the highest CAGR during the forecast period

The rabies immunoglobulins segment is expected to witness significant growth over the forecast period driven by increasing awareness of rabies prevention, a rising incidence of rabies in certain regions, and improved production techniques. Governments and healthcare organizations have initiated rabies control programs to address this public health concern. Moreover, ongoing research and development efforts aim to enhance the efficiency and affordability of rabies immunoglobulins. The critical role that rabies immunoglobulins play in preventing and treating rabies ensures their continued growth within the broader hyperimmune globulins market.

Region with largest share:

The market for Hyperimmune Globulins in North America is expected to witness robust growth in recent years. This surge can be attributed to rising awareness about passive immunization, especially in high-risk populations. Increasing incidence of infectious diseases and the need for immediate, targeted immunity have driven demand. Additionally, strategic collaborations between healthcare institutions, research organizations, and pharmaceutical companies have accelerated research and development efforts. With a well-established healthcare infrastructure, stringent regulatory framework, and growing healthcare expenditure, North America is poised to continue leading in hyperimmune globulins market growth.

Region with highest CAGR:

During the forecast period, North America is anticipated to witness lucrative growth. Hyperimmune globulins play a critical role in healthcare throughout the Asia-Pacific region. These specialized antibody preparations are vital for addressing and preventing a range of infectious diseases prevalent in this diverse and populous area. Diseases like hepatitis B, rabies, and tetanus are significant public health concerns. Moreover, Asia-Pacific's vast geographic and demographic diversity underscores the importance of these preparations in safeguarding public health and mitigating the impact of infectious diseases, making them an essential component of the healthcare landscape in the region.

Key players in the market:

Some of the key players in Hyperimmune Globulins market include: ADMA Biologics, Biotest, China National Biotec Group Company Limited (CNBG), CSL Behring, Emergent (Cangene), Grifols, Hualan Bio, Kamada, Kedrion, Shanghai Raas Blood Products Co. Ltd and Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.

Key Developments:

In July 2023, Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, has announced that China's National Institutes for Food and Drug Control (NIFDC) has approved BPL's human Albumin product for release to the Chinese market. In 2022, Kedrion joined forces with BPL, a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines for the treatment of rare diseases.

In March 2023, Grifols entered into a collaboration and licensing agreement with Selagine to develop immunoglobulin (Ig) eye drops to treat dry eye disease. Under the terms of the agreement, Grifols will have worldwide exclusive commercial rights to Selagine's treatment once it receives the regulatory authorization, expected in early 2029.

In January 2022, LFB and Kedrion signed an industrial cooperation agreement to supply immunoglobulins to meet patient demand in France. Two leading European pharmaceutical companies, LFB and Kedrion, are joining forces in an industrial cooperation agreement to increase the availability of immunoglobulin, a plasma-derived medicine, for patients in France.

Types Covered:

• Hepatitis B Immunoglobulins
• Rabies Immunoglobulins
• Rho(D) Immunoglobulins
• Tetanus Immunoglobulins
• Other Types

End Users Covered:

• Hospitals & Clinics
• Blood Banks and Donation Centers
• Government Institutions
• Home Healthcare
• Pharmaceutical Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Hyperimmune Globulins Market, By Type

• 5.1 Introduction
• 5.2 Hepatitis B Immunoglobulins
• 5.3 Rabies Immunoglobulins
• 5.4 Rho(D) Immunoglobulins
• 5.5 Tetanus Immunoglobulins
• 5.6 Other Types

6 Global Hyperimmune Globulins Market, By End User

• 6.1 Introduction
• 6.2 Hospitals & Clinics
• 6.3 Blood Banks and Donation Centers
• 6.4 Government Institutions
• 6.5 Home Healthcare
• 6.6 Pharmaceutical Companies
• 6.7 Other End Users

7 Global Hyperimmune Globulins Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 ADMA Biologics
• 9.2 Biotest
• 9.3 China National Biotec Group Company Limited (CNBG)
• 9.4 CSL Behring
• 9.5 Emergent (Cangene)
• 9.6 Grifols
• 9.7 Hualan Bio
• 9.8 Kamada
• 9.9 Kedrion
• 9.10 Shanghai Raas Blood Products Co. Ltd
• 9.11 Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.